AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

By Yahoo! Finance | Jul 8, 2024 at 01:56 AM EST

AB Science reports positive results from Phase 2 study of masitinib in COVID-19 patients. Study showed promising efficacy in improving clinical status with odds ratio of 2.4. Safety profile aligns with known data. Future evaluation and partnerships are being considered.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.